跳至主要内容
临床试验/CTRI/2009/091/000118
CTRI/2009/091/000118已完成3 期

A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma Who Smoke Cigarettes.

Merck Co Inc2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2009年6月29日最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
Merck Co Inc
入组人数
1,000
试验地点
2
主要终点
Percentage of asthma-control days over the 6-month treatment period

研究概览

简要总结

Number of Indian subjects proposed for enrollment in this global study is 30 Date of first enrollment (India)- 29 Jun 2009

研究设计

研究类型
Interventional
分配方式
Stratified block randomization
盲法
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

入排标准

年龄范围
18.00 Year(s) 至 55.00 Year(s)(—)
性别
All

入选标准

  • Patients with chronic asthma who actively smoke at least 0.5 to no more than 2 packs of cigarettes a day.

排除标准

  • Patient can not have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or emphysema.

结局指标

主要结局

Percentage of asthma-control days over the 6-month treatment period

时间窗: Time Frame: 6 months [ Designated as safety issue: No ]

次要结局

  • AM Peak Expiratory Flow Rate (PEFR) and daytime symptom score over the 6-month treatment period(Time Frame: 6 months [ Designated as safety issue: No ])

研究者

发起方
Merck Co Inc
申办方类型
Pharmaceutical industry-Global

研究点 (2)

Loading locations...

相似试验